By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Former first lady Jill Biden is offering a candid look at the challenges facing former President Joe Biden as he ...

New Jersey hospitals expand prostate cancer treatment with robotics, proton therapy and precision medicine innovations.

The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Prostate health is vital for men over fifty as conditions like BPH, prostatitis, and cancer can affect urinary function and ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through the Brazilian Unified Health System (SUS) over a 16-year period, between ...

Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and ...